Thus, these results indicate that C-MYC/HDAC5/SOX9 axis plays a critical role in maintaining tamoxifen resistance in breast cancer, which might be the potential target for reversing the tamoxifen resistance. Here, HDAC5 is linked to breast carcinoma.